Viking registers two Phase 3 trials for oral VK2735 in weight management
Viking Therapeutics listed SUNRISE 1 and SUNRISE 2, both Phase 3 studies of oral VK2735, on October 9, 2026.
Viking Therapeutics registered two new Phase 3 trials for its oral dual GLP-1/GIP agonist VK2735, both listed as not yet recruiting.
- SUNRISE 2 (NCT07868939) is a Phase 3 trial of oral VK2735 in adults with type 2 diabetes mellitus who are obese or overweight. The study is one of two planned Phase 3 studies meant to support a weight management indication for VK2735 Oral in this population.1 The trial is estimated to enroll 560 participants1 and has a primary completion estimated for October 2028.
- SUNRISE 1 (NCT07868835) is a Phase 3 trial of oral VK2735 in adults without type 2 diabetes mellitus who are obese or overweight with at least one weight-related comorbid condition. The trial is one of two planned Phase 3 studies supporting the weight management indication for VK2735 Oral in obese or overweight adults with at least one weight-related comorbidity.2 It is also estimated to enroll 560 participants2, with primary completion estimated for July 2028.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.